Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Public ClinicalTrials.gov record NCT04150497. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Study identification
- NCT ID
- NCT04150497
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Cellectis S.A.
- Industry
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Interventions
- CLLS52 Biological
- UCART22 Biological
Biological
Eligibility (public fields only)
- Age range
- 15 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2019
- Primary completion
- Jun 29, 2026
- Completion
- Jun 29, 2026
- Last update posted
- Sep 8, 2025
2019 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Los Angeles (UCLA) - Medical Center | Los Angeles | California | 90095 | Recruiting |
| University of Colorado - Aurora Cancer Center | Aurora | Colorado | 80045 | Recruiting |
| Sarah Cannon - Colorado Blood Cancer Institute | Denver | Colorado | 80218 | Recruiting |
| University of Chicago | Chicago | Illinois | 60647 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | Recruiting |
| Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | Recruiting |
| Weill Medical College of Cornell University | New York | New York | 10065 | Withdrawn |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Sarah Cannon - HCA Research Institute | Nashville | Tennessee | 37203 | Recruiting |
| Sarah Cannon - St. David's South Austin Medical Center | Austin | Texas | 78704 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Sarah Cannon - Texas Transplant Institute at Methodist Hospital | San Antonio | Texas | 78229 | Recruiting |
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04150497, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2025 · Synced Apr 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04150497 live on ClinicalTrials.gov.